Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

• Status: Recruiting
• Trial end date: 2026-12-31

Summary

The goal of this clinical trial is to compare the efficacy and safety of a Contezolid and Delamanid-Containing short regimen to standard longer regimen in Rifampicin-resistant pulmonary tuberculosis (RR-TB). The main questions it aims to answer are:

• Is the efficacy of short regimen non-inferior to standard regimen?

• Is the short regimen safe enough to replace the standard regimen?

Participants will:

• Be given with either short or standard regimen for RR-TB treatment

• Be asked to complete the scheduled visit as planned.

• Phase: Phase 3

Details

• Lead Sponsor: Beijing Chest Hospital
• Collaborator: National Medical Center for Infectious Diseases
• Treatments: Aminosalicylic Acid; Bedaquiline; Clofazimine; Cycloserine; Ethambutol; Levofloxacin; Linezolid; Moxifloxacin; Prothionamide; Pyrazinamide